Gritstone Oncology
San Carlos, US · Founded 2015 · 27 employees on LinkedIn · 4 known investors
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma. The company works at the intersection of cancer genomics and immunotherapy and is based at MBC Biolabs in San Carlos, California.
Founders & leadership
W
WayneCEO
R
RachelVP of Operations
Investors · 4
In the news
Frequently asked questions
- What does Gritstone Oncology do?
- Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma. The company works at the intersection of cancer genomics and immunotherapy and is based at MBC Biolabs in San Carlos, California.
- Who are Gritstone Oncology's investors?
- Gritstone Oncology's investors include Bay City Capital, GV (Google Ventures), LAV, Lilly Asia Ventures.
- Where is Gritstone Oncology headquartered?
- Gritstone Oncology is headquartered in San Carlos, US.